These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26623270)

  • 21. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
    Agrawal S; Duseja A
    Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic therapy for nonalcoholic fatty liver disease in adults.
    Malinowski SS; Byrd JS; Bell AM; Wofford MR; Riche DM
    Pharmacotherapy; 2013 Feb; 33(2):223-42. PubMed ID: 23359475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Khan FZ; Perumpail RB; Wong RJ; Ahmed A
    World J Hepatol; 2015 Aug; 7(18):2155-61. PubMed ID: 26328027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Future of Nonalcoholic Fatty Liver Disease Treatment.
    Mazhar K
    Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease.
    Hjelkrem MC; Torres DM; Harrison SA
    Minerva Med; 2008 Dec; 99(6):583-93. PubMed ID: 19034256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy of nonalcoholic fatty liver disease: current status.
    Duvnjak M; Tomasic V; Gomercic M; Smircic Duvnjak L; Barsic N; Lerotic I
    J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():57-66. PubMed ID: 20388946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microcirculatory disturbances and cellular changes during progression of hepatic steatosis to liver tumors.
    Liebig M; Hassanzada A; Kämmerling M; Genz B; Vollmar B; Abshagen K
    Exp Biol Med (Maywood); 2018 Jan; 243(1):1-12. PubMed ID: 29065724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic Fatty Liver Disease.
    Wang XJ; Malhi H
    Ann Intern Med; 2018 Nov; 169(9):ITC65-ITC80. PubMed ID: 30398639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease - current status and future directions.
    Demir M; Lang S; Steffen HM
    J Dig Dis; 2015 Oct; 16(10):541-57. PubMed ID: 26406351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic fatty liver disease: from clinical recognition to treatment.
    Sevastianos VA; Hadziyannis SJ
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):59-79. PubMed ID: 19072371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter.
    Conjeevaram Selvakumar PK; Kabbany MN; Alkhouri N
    Paediatr Drugs; 2018 Aug; 20(4):315-329. PubMed ID: 29740791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
    Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
    Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis.
    Mummadi RR; Kasturi KS; Chennareddygari S; Sood GK
    Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1396-402. PubMed ID: 18986848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
    Carr RM; Oranu A; Khungar V
    Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.